Following is a cumulative list of Hoosier Cancer Research Network publications in lung cancer.

Manuscripts and Journal Articles

• Xiuning Le, Jyoti D. Patel, Elaine Shum, Christina Baik, Rachel E. Sanborn, Catherine A. Shu, Chul Kim, Mary Jo Fidler, Richard Hall, Yasir Y. Elamin, Janet Tu, George Blumenschein, Jianjun Zhang, Don Gibbons, Carl Gay, Nisha A. Mohindra, Young Chae, Yanis Boumber, Joshua Sabari, Rafael Santana-Davila, Shane Rogosin, Benjamin Herzberg, Ben Creelan, Bruna Pellini, Tawee Tanvetyanon, Simon Heeke, Mike Hernandez, Jhanelle E. Gray, Andreas Saltos, John V. Heymach.A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial): Hoosier Cancer Research Network LUN18-335. DOI: 10.1200/JCO.24.00533 Journal of Clinical Oncology. 2024 October. See Abstract. 
• Ryan Gentzler, Nisha Mohindra, Shadia Jalal, Karen Reckamp, Richard Hall, Nasser Hanna, Young Kwang Chae, Marianna Koczywas, Irene Helenowski, Jyoti Patel. Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non–Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175. DOI: 10.1093/oncolo/oyad180 The Oncologist. 2024 January. See Abstract. 
• Arkadiusz Dudek, Min Xi, Katherine Scilla, Hirva Mamdani, Benjamin Creelan, Andreas Saltos, Tawee Tanvetyanon, Alberto Chiappori. Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: Hoosier Cancer Research Network LUN15-299. DOI: 10.1016/j.jtocrr.2023.100584 JTO Clinical Research Reports. 2023 October 11. See Abstract. 
• Durm, GA, Jabbour, SK, Althouse, SK, Liu, Z, Sadiq, AA, Zon, RT, Jalal, SI, Kloecker, GH, Williamson, MJ, Reckamp, KL, Langdon, RM, Kio, EA, Gentzler, RD, Adesunloye, BA, Harb, WA, Walling, RV, Titzer, ML, Hanna, NH. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN14-179. Cancer. 2020: 126: 4353– 4361. https://doi.org/10.1002/cncr.33083. See abstract.
• Bilal Anouti, Sandra Althouse, Greg Durm, Nasser Hanna. Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN14-179. Clinical Lung Cancer, Volume 21, Issue 3, 2020, Pages 288-293, ISSN 1525-7304, https://doi.org/10.1016/j.cllc.2019.06.009. See abstract.
• S.S. Ahmed, G.A. Durm, J. Donatelli, Y. Liu, H. Yao, C. Desrosiers, Z. Liu, F.M. Kong, N. Hanna. Potential Predictors of Pembrolizumab Associated Pneumonitis: A Retrospective Review of the HCRN LUN14-179 Trial. Journal of Thoracic Oncology, Volume 12, Issue 11, S1552. See abstract.
• S.I. Jalal, N.H. Hanna, R. Zon, G.A. Masters, H. Borghaei, K. Koneru, S.S. Badve, N.K Prasad, N. Somaiah, J. Wu, Z. Yu, L.H. Einhorn. Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies: LUN07-130. Am J Clin Oncol Cancer Clinical Trials. 2014 Dec 10. Epub 2014 Dec 10. PMID: 25503432
• Jalal SI, Riggs HD, Melnyk A, Richards D, Agarwala A, Neubauer M, Ansari R,Govindan R, Bruetman D, Fisher W, Breen T, Johnson CS, Yu M, Einhorn L, Hanna N. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology LUN01-24. Ann Oncol. 2012 Jul;23(7):1730-8. doi: 10.1093/annonc/mdr565. Epub 2011 Dec 9.
• Riggs H, Jalal SI, Baghdadi TA, Bhatia S, McClean J, Johnson C, Yu M, Taber D, Harb W, Hanna N. Erlotinib and Bevacizumab in Newly Diagnosed Performance Status 2 or Elderly Patients With Nonsquamous Non-Small-Cell Lung Cancer, a Phase II Study of the Hoosier Oncology Group: LUN04-77. Clin Lung Cancer. 2012 Oct 24. doi:pii: S1525-7304(12)00201-X. 10.1016/j.cllc.2012.09.004. [Epub ahead of print] PubMed PMID: 23102811
• Barriger, Bryan; Fakiris, Achilles; Hanna, Nasser; Yu, Menggang; Mantravadi, Prasad; McGarry, Ronald. Dose Volume Analysis of Radiation Pneumonitis in Non-Small Cell Lung Cancer Patients Treated with Concurrent Cisplatinum and Etoposide with or without Consolidation Docetaxel LUN01-24. Int. J. Radiation Oncology Biol. Phys., Vol. 78, No. 5, pp. 1381–1386, 2010 Mar 13
• Jalal, Shadia; Bedano, Pablo; Einhorn, Lawrence; Bhatia, Sumeet; Ansari, Rafat; Bechar, Naftali; Koneru, Karuna; Govindan, Ramaswamy; Wu, Jingwei; Yu, Menggang; Schneider, Bryan; Hanna, Nasser. Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group LUN05-99. Journal of Thoracic Oncology. 5(12):2008-2011, December 2010. doi: 10.1097/JTO.0b013e3181f77b6e. See abstract.
• S. Jalal, D.Waterhouse, M. J. Edelman, S. Nattam, R. Ansari, K. Koneru, R. Clark, A. Richards, J. Wu, M. Yu, B. Bottema, A. White, N. Hanna. Pemetrexed plus Cetuximab in patients with Recurrent Non-Small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group LUN04-79. Journal of Thoracic Oncology. Volume 4, Number 10, October 2009.
• Jalal, Shadia MD; Ansari, Rafat MD; Govindan, Ramaswamy MD; Bhatia, Sumeet MD; Bruetman, Daniel MD; Fisher, William MD; Masters, Gregory MD; White, Angela MBA; Stover, Daniel MT ; Yu, Menggang PhD; Hanna, Nasser MD. Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study LUN04-78. Journal of Thoracic Oncology. 4(1):93-96, January 2009.
• N. Hanna, M. Neubauer, C. Yiannoutsos, R. McGarry, J. Arseneau, R Ansari, C. Reynolds, R. Govindan, A. Melnyk, W. Fisher, D. Richards, D. Bruetman, T. Anderson, N. Chowhan, S. Nattam, P. Mantravadi, C. Johnson, T. Breen, A. White, L. Einhorn, Cisplatin plus Etoposide plus Concurrent Chest Radiation with or without Consolidation Docetaxel in Patients with Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC) LUN01-24: A Randomized Phase III Study from the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008 Dec 10;26(35):5755-60. Epub 2008 Nov 10.
• Anuj Agarwala, William Fisher, Daniel Bruetman, John McClean, David Taber, Michael Titzer, Beth Juliar, Menggang Yu, Tim Breen, Lawrence Einhorn, Nasser Hanna. Gefitinib plus Celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group LUN02-50. J Thorac Oncol 2008;3:374-379.
• Ademuyiwa F, Johnson C, White A, Breen T, Harvey J, Neubauer M, Hanna N. Prognostic factors in stage III non-small cell lung cancer LUN01-24. Clin Lung Ca 2007;8:478-82
• Hanna, Nasser; Neubauer, Marcus; McGarry, Ronald; Govindan, Ramaswamy; Johnson, Cynthia; Yiannoutsos, Constantin; Breen, Tim; White, Angela; Ansari, Rafat; Einhorn, Lawrence.Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): LUN01-24/USO-023: B5-01: Journal of Thoracic Oncology. 2(8):S346, August 2007
• A.M. Moore, L.H. Einhorn, D. Estes, R. Govindan, J. Axelson, J. Vinson, T. E. Breen, M. Yu, N.H. Hanna. Gefitinib in Patients with Chemo-sensitive and Chemo-refractory Relapsed Small Cell Cancers: A Hoosier Oncology Group Phase II Trial LUN02-50. Lung Cancer (2006) 52, 93-97
• Nasser Hanna, Paul Bunn, Jr., Corey Langer, Lawrence Einhorn, Troy Guthrie, Jr., Thaddeus Beck, Rafat Ansari, Peter Ellis, Michael Byrne, Mark Morrison, Subramanian Hariharan, Benjamin Wang, Alan Sandler. Randomized Phase II Trial Comparing Irinotecan/Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer LUN00-12. J Clin Oncol 2006; 24:2038-2046
• Hanna N, Shepherd F, Fossella F, Pereira J, De Marinis F, von Pawel J, Gatzemeier U, Tsao T, Pless M, Muller T, Lim H, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn P. Randomized Phase III Trial of Pemetrexed versus Docetaxel in Patients with Non-small Cell Lung Cancer Previously Treated with Chemotherapy LUN01-15. J Clin Oncol 2004;22:1589-1597
• Sumeet Bhatia, Nasser Hanna, Rafat Ansari, Lawrence Einhorn, Alan Sandler. Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC: A Hoosier Oncology Group (HOG) phase II study LUN97-1. Lung Cancer 38 (2002): 85-89.
• Sumeet Bhatia, Nasser Hanna, Rafat Ansari, William Pletcher, Lawrence Einhorn, Elizabeth Ng, Alan Sandler. A Phase II Study of Gemcitabine Plus Paclitaxel in Patients With Previously Untreated Stage IIIb and IV Non-Small Cell Lung Cancer LUN98-1. Lung Cancer 38 (2002): 73-77.
• Hanna N, Ansari R, Fisher W, Shen J, Jung S, Sandler A. Etoposide, Ifosfamide and Cisplatin (VIP) plus Concurrent Radiation Therapy for Previously Untreated Limited Small Cell Lung Cancer (SCLC): A Hoosier Oncology Group (HOG) Phase II study. Lung Cancer 35 (3): 293-297, 2002.
• Hanna NH, Sandler AB, Loehrer Sr. PJ, Ansari R, Jung SH, Lane K, Einhorn LH. Maintenance Daily Oral Etoposide versus No Further Therapy Following Induction Chemotherapy with Etoposide plus Ifosfamide plus Cisplatin in Extensive Small-Cell Lung Cancer: A Hoosier Oncology Group (Randomized) Trial LUN93-2. Annals of Oncology 13: 95-102, 2002.
• Sonpavde G, Ansari R, Walker P, Sciortino D, Gabrys G, Murdock A, Gonin R, Einhorn L. Phase II Study of Doxorubicin and Paclitaxel as Second-Line Chemotherapy of Small-Cell Lung Cancer: A Hoosier Oncology Group Trial LUN96-1. American Journal of Clinical Oncology. 23(1):68-70, 2000 Feb.
• Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. (LUN95-1) J Clin Oncol. 2000 Jan;18(1):122-30. See abstract.
• Ng E, Sandler A, Robinson L, Einhorn LH. A Phase II Study of Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung Cancer (NSCLC). A Hoosier Oncology Group Study LUN96-2. American Journal Clinical Oncology, 22(6):550-553, 1999.
• Sandler A, Blanke C, Monaco F, Carey MA, Ansari R, Fisher B, Spiridonidis CH, Einhorn L, Nichols C. A Phase II Trial of CODE (Cisplatin, Vincristine, Doxorubicin, Etoposide) Plus Granulocyte-Colony Stimulating Factor (G-CSF) in Advanced Non-Small Cell Lung Cancer LUN91-2. Am J Clin Oncol 21:294-297, 1998.
• Sandler AB, Nguyen B, Ansari R, McClean J, Fisher W, Einhorn LH: A Phase II Study of Gemcitabine and Cisplatin in Patients with Non-Small Cell Lung Cancer LUN93-4. Semin Oncol 24: June, 1997.
• Einhorn LH: Phase II Trial of Gemcitabine Plus Cisplatin in NSCLC: A Hoosier Oncology Group Study LUN93-4. Semin Oncol 24:24-26, 1997.
• Einhorn LH, and Loehrer PJ: Hoosier Oncology Group Studies in Extensive and Recurrent Small Cell Lung Cancer. Semin Oncol 22:28-31, 1995.
• Loehrer PJ, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, Einhorn LH: Cisplatin Plus Etoposide With and Without Ifosfamide in Extensive Small-Cell Lung Cancer: A Hoosier Oncology Group Study LUN93-2. J Clin Oncol 13:2594-2599, 1995
• Blanke C, Ansari R, Tokars R, Fisher W, Pennington K, Mantravadi R, O’Connor T, Rynard S, Miller M, Einhorn L. A Phase III Trial of Thoracic Irradiation with or without Cisplatin for Locally Advanced Unresectable Non-small Cell Lung Cancer (NSCLC): A Hoosier Oncology Group Protocol LUN86-1. J of Clin Oncol 13(6):1425-1429, 1995.
• Faylona EA, Loehrer PJ, Ansari R, Sandler AB, Gonin R, Einhorn LH. Daily Oral Etoposide Plus Ifosfamide Plus Cisplatin for Previously Treated Recurrent Small-Cell Lung Cancer: A Hoosier Oncology Group Trial. J Clin Oncol 13:1209-1214, 1995.
• Blanke C, Ansari R, Tokars R, Fisher W, Pennington K, Mantravadi R, O’Connor T, Rynard S, Miller M, Einhorn L. A Phase III Trial of Thoracic Irradiation with or without Cisplatin for Locally Advanced Non-small Cell Lung Cancer (NSCLC): A Hoosier Oncology Group Protocol LUN86-1. In: Salmon S ed. Adjuvant Therapy of Cancer VII. Philadelphia: JB Lippincott, 1993:125-131.
• Loehrer Sr PJ, Ansari R and Einhorn LH: Extensive Small Cell Lung Cancer: Trials of Indiana University and the Hoosier Oncology Group. Lung Cancer 9:41-49, 1993.
• Mandanas R, Einhorn LH, Wheeler B, Ansari R, Lutz T, Miller ME: Carboplatin (CBDCA) Plus Alpha Interferon in Metastatic Non-Small Cell Lung Cancer: A Hoosier Oncology Group (HOG) Phase II Trial LUN90-1. Am J Clin Oncol (CCT) 16(6):519-521, 1993.
• Loehrer PJ, Rynard SM, Ansari R, Songer J, Pennington K, Einhorn LH: Etoposide Plus Ifosfamide Plus Cisplatin (VIP) in Extensive Small-cell Lung Cancer LUN87-1. Cancer 69:669-673, 1992
• Eklund E, Miller M, Ansari R, Fisher W, Einhorn LH: Phase II Trial of High Dose Cisplatin Plus Etoposide Plus Vinblastine in Non Small Cell Lung Cancer: A Hoosier Oncology Group Study. Am J Clin Oncol14:412-45, 1991.
• Saxman S, Loehrer PJ, Logie K, Stephens D, Workman F, Scullin D, Einhorn LH, Ansari R: Phase II Trial of Daily Oral Etoposide in Patients with Advanced Non Small Cell Lung Cancer. (LUN88-6) Invest. New Drugs 9: 253-256, 1991. See abstract.
• Einhorn LH, Pennington K, McClean J: Phase II Trial of Daily Oral VP l6 in Refractory Small Cell Lung Cancer: A Hoosier Oncology Group Study. Semin Oncol l7:32-35, 1990.
• Lauer RC, Fisher WB, Pennington K, Ansari R, Einhorn LH, Loehrer PJ: Etoposide and Split Dose-Cisplatin in Bronchogenic Carcinoma. Am J Clin Oncol ll:634 5, l988.

Abstracts, Posters, and Presentations

• H Mamdani, S Kim, R Gentzler, M Shields, M Furqan, K Pizana, Q Abid, S Ibrahim. A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study. Presented as a poster at 2024 ASCO. See abstract. 
• X Le, J Patel, E Shum, J Sabari, C Baik, R Sanborn, K Shu, C Kim, M Jo Fidler, R Hall, N Hanna, J Gray, JV Heymach, A Saltos. LBA71 – A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)(HCRN-LUN18-335). Presented as a mini oral session at the 2023 EMSO Congress. See abstract. 
• N Shukla, SK Althouse, AA Sadiq, SI Jalal, SK Jabbour, R Zon, GH Kloecker, WB Fisher, KL Reckamp, EA Kio, RM Langdon, B Adesunloye, RD Gentzler, NH Hanna, GA Durm. The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC: an analysis from HCRN LUN14-179. Presented as a poster at the 2020 American Society of Clinical Oncology Annual Meeting. See abstract.
• A. Saltos, C. Baik, R.E. Sanborn, E. Shum, C. Kim, R. Hall, M.J. Fidler, C.A. Shu, G. Otterson, J. Patel, K.K. Wong, N. Hanna, J. Gray, J. Heymach, X. Le. RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC. (HCRN LUN18-335). Presented at the IASLC 2020 World Conference on Lung Cancer. See abstract.
• R. Gentzler, N. Mohindra, S. Jalal, K. Reckamp, R. Hall, N. Hanna, Y.K. Chae, V. Villaflor, M. Koczywas, I. Helenowski, A. Rademaker, J. Patel. Ph I/II Carboplatin, Nab-Paclitaxel and Pembrolizumab for Advanced NSCLC (HCRN LUN13-175): Outcomes by Nab-Paclitaxel Dose. Presented at the IASLC 2019 World Conference on Lung Cancer. See abstract.
• G. Durm, S. Althouse, A. Sadiq, S. Jalal, S. Jabbour, R. Zon, G. Kloecker, M. Williamson, K. Reckamp, E. Kio, R. Langdon, B. Adesunloye, R. Gentzler, W. Harb, R. Walling, C. Yeon, M. Koczywas, N. Hanna. P1.18-05 ChemoXRT w/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy LUN 14-179. Presented at the IASLC 2019 World Conference on Lung Cancer. See abstract.
• GA Durm, SK Althouse, AA Sadiq, SI Jalal, S Jabbour, R Zon, GH Kloecker, WB Fisher, KL Reckamp, EA Kio, RM Langdon, B Adesunloye, RD Gentzler, NH Hanna. Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Presented at the Oral Abstract Session at the 2018 ASCO Annual Meeting on Monday, June 4, 2018. J Clin Oncol 36, 2018 (suppl; abstr 8500). See abstract.
• G.A. Durm, E.A. Kio, W.B. Fisher, M.L. Titzer, S.Jabbour, T. Breen, Z.Liu, N.H. Hanna. Phase II trial of consolidation Pembrolizumab following concurrent chemoradiation in patients (pts) with unresectable or inoperable stage III non-small cell lung cancer (NSCLC): initial safety data from HCRN LUN 14-179. Accepted as a publication-only abstract at the ASCO Annual Meeting, June 3-7, 2016, Chicago IL. J Clin Oncol 34, 2016 (suppl; abstr e20025). See abstract.
• S.I. Jalal, N.H. Hanna, R. Zon, G.A. Masters, H. Borghaei, K. Koneru, S.S. Badve, N.K Prasad, N. Somaiah, J. Wu, Z. Yu, L.H. Einhorn. Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies: HOG LUN07-130. Presented at the general poster session, lung cancer – non-small cell local -regional/ small cell/other thoracic cancers at the ASCO Annual Meeting, May 30 – June 3, 2014, Chicago IL.
  J Clin Oncol 32:5s, 2014 (suppl; abstr 7594)
• R.E. Sanborn, J.D. Patel, G.A. Masters, N. Jayaram, A.W. Stephens, M.J. Guarino, J.G. Misleh, C.E. Williams, J. Wu, N.H. Hanna. A randomized double-blind phase II trial of platinum (P) plus etoposide (E) with or without concurrent ZD6474 (Z) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC): Hoosier Oncology Group LUN06-113. Presented at the oral abstract session, lung cancer – non-small cell local-regional/small cell/other thoracic cancers at the ASCO Annual Meeting, May 30 – June 3, 2014, Chicago IL. J Clin Oncol 32:5s, 2014 (suppl; abstr 7506)
• S. Jalal, J. Bufill, M. Guarino , N. Somaiah , K. Koneru, J. McClean, R.Sanborn, J. Wu, Z. Yu, L. Einhorn. A phase I study of Amrubicin (AMR) and Cyclophosphamide in patients with advanced solid organ malignancies: A trial from the Hoosier Oncology Group LUN07-130. Accepted as a Poster Presentation at the General Poster Session at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr 7082)
• D. Bodenmiller, S. Jalal, J. Turchi, J. Wu, Z. Yu, L. Einhorn. A phase I study of Amrubicin (AMR) and Cyclophosphamide in patients with advanced solid organ malignancies: Correlative analysis of a trial from the Hoosier Oncology Group LUN07-130. Accepted as abstract (Abstract # e17517) at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL.
• J. Feliciano, N. Hanna, A. Fakiris, M. Yu, W. Dugan, J. McClean, J. Bufill, S. Bhatia, J. Patel. A phase II Study of concurrent pemetrexed and radiation for poor risk stage III non-small cell lung cancer (NSCLC): Hoosier Oncology Group LUN08-129. Accepted as abstract (Abstract # e17529) at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL.
• N. H. Jayaram, M. A. Neubauer, C. S. Johnson, T. Breen, C. E. Williams, N. H. Hanna. The impact of PET imaging on outcomes in patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation: A subset analysis of HOG LUN01-24/USO-023. Accepted to the general poster session at the ASCO Annual Meeting June 4-8, 2010. J Clin Oncol 28:15s, 2010 (suppl; abstr 7065)
• T. Al Baghdadi, S. Bhatia, W. Harb, J. Maher, J. McClean, S. Nattam, D. Taber, M. Yu, C. Johnson and N. Hanna. Erlotinib and bevacizumab in chemotherapy naïve performance status 2 patients with advanced non-small-cell lung cancer LUN04-77. Accepted (abstract #e19082) at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL
• R. B. Barriger, J. C. Aseneau, M. Yu, C. Reynolds, P. Mantravadi, M. Neubauer, A. J. Fakiris, A. White, N. Hanna, R. C. McGarry. Rates and Risk of Pneumonitis in Non-Small Cell Lung Carcinoma (NSCLC) Patients (pts) Treated with Concurrent Chemoradiation LUN01-24. Submitted to the ASTRO Annual Meeting, September 21-25, 2008, Boston, MA.
• L. Mina, M. Neubauer, R. Ansari, R. Govindan, L. Einhorn, W. Fisher, D. Bruetman, N. Chowhan, C. Johnson, N. Hanna. Phase III Trial of Cisplatin (P) plus Etoposide (E) plus Concurrent Chest Radiation (XRT) with or without Consolidation Docetaxel (D) in Patients (pts) with Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): LUN01-24/USO-023; Updated Results. Accepted as a poster presentation to the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL
• S. Jalal, S. Bhatia, L. Einhorn, R. Ansari, N. Bechar, R. Govindan, K. Koneru, P. Bedano, J. Wu, N. Hanna. Paclitaxel (P) plus bevacizumab (B) in patients (pts) with Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy trial from the Hoosier Oncology Group LUN05-99. Accepted to the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL
• S. Jalal, D. Waterhouse, M. Edelman, S. Nattam, R. Ansari, K. Koneru, M. Yu, J. Shen, T. Breen, N. Hanna: Pemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): a phase I-IIa dose-ranging study from the Hoosier Oncology Group LUN04-78. Poster accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.
• V. Cook, N. Hanna, T. Breen, A. White, J. Wu: Predictors of toxicity to consolidation docetaxel (D) following cisplatin (P) plus etoposide (E) plus concurrent radiation (XRT) in patients (pts) with stage III non-small cell lung cancer (NSCLC) treated on a phase III randomized trial LUN01-24. Abstract accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.
• N. Hanna, M. Neubauer, R. McGarry, C. Johnson, C. Yiannoutso, T. Breen, A. White, R. Ansari, L. Einhorn, R. Govindan: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): LUN01-24. Presentation at 12th World Conference on Lung Cancer, Seoul, Korea September 2-6, 2007.
• F. Ademuyiwa, C. Johnson, A. White, T. Breen, J. Harvey, M. Neubauer, N.Hanna: Prognostic Factors For Survival In Patients With Unresectable Stage III Non-Small Cell Lung Cancer From a Phase III Randomized Trial From The Hoosier Oncology Group LUN01-24. Poster accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.
• M. M. Sgroi, M. Neubauer, R. Ansari, R. Govindan, D. Bruetman, W. Fisher, C. Johnson, T. Breen, C. Yiannoutsos, N. Hanna:An analysis of elderly patients (pts) treated on a phase III trial of cisplatin (P) plus etoposide (E) with concurrent radiotherapy (CRT) followed by docetaxel (D) vs observation (O) in pts with stage III non small cell lung cancer (NSCLC) LUN01-24. Poster accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.
• F.O. Ademuyiwa, N. Hanna, C. Johnson, T. Breen, C. Yiannoutsos, A. White. Multivariate Analysis of Prognostic Variables Associated with Survival from a Phase III Study of Cisplatin (P) plus Etoposide (E) plus Chest Radiation (XRT) with or without Consolidation Docetaxel (D) in Patients with Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) LUN01-24. Poster accepted to the 7th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, CA – February 22-24, 2007
• N. Hanna, M. Neubauer, R. Ansari, R. Govindan, D. Bruetman, W. Fisher, N. Chowhan, S. Nattam, C. Yiannoutsos, L. Einhorn: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): LUN01-24. Poster presentation at Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.
• P. Bedano, M. Edelman, S. Nattam, D. Waterhouse, J. Shen, M. Yu, J. Harvey, J. Vinson, A. White, B. Bottema, N. Hanna. A Phase I-IIa Dose Ranging Study of Pemetrexed plus Cetuximab in Patients (pts) with Recurrent Non-Small Cell Lung Cancer (NSCLC): Analysis of the Completed Phase I Portion of HOG LUN04-79. Poster presentation at the 4th IASLC International Chicago Symposium on Malignancies of the Chest and Head and Neck, October 26-28, 2006.
• A. Agarwala, L. Einhorn, W. Fisher, D. Bruetman, J. McClean, D. Taber, M. Titzer, B. Juliar, T. Breen, N. Hanna. Gefitinib plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC): A Phase II Study from the Hoosier Oncology Group LUN02-50. Presented as part of the Scientific Program in the Lung Cancer General Poster Session 2006 Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006, Atlanta, Georgia
• N. Hanna, R. Ansari, S. Bhatia, R. Govindan, D. Bruetman, M. Guarino, W. Fisher, A. White, T. Breen, B. Juliar. Pemetrexed in Patients (pts) with Relapsed Small Cell Lung Cancer (SCLC): A Phase II Study from the Hoosier Oncology Group LUN04-78. Presented as part of the Scientific Program in the Lung Cancer General Poster Session 2006 Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006, Atlanta, Georgia
• P. Bedano, M. Neubauer, R. Ansari, R. Govindan, L. Einhorn, D. Bruetman, A. White, T. Breen, B. Juliar, N. Hanna. Phase III Study of Cisplatin (P) plus Etoposide (E) with Concurrent Chest Radiation (XRT) followed by Docetaxel (D) vs. Observation in Patients (pts) with Stage III Non-small Cell Lung Cancer (NSCLC): An Interim Toxicity Analysis of Consolidation Therapy LUN01-24. Presented as part of the Scientific Program in the Lung Cancer General Poster Session 2006 Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006, Atlanta, Georgia
• A Sandler, C Langer, P Bunn, L Einhorn. Interim Safety Analysis of Irinotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive Small Cell Lung Cancer LUN00-12. Accepted to the ASCO annual meeting May 13-17, 2005 in Orlando, Florida
• A Auperin, C Le Pechoux on behalf of the MAC3-LC Group. Meta-analysis of randomized trials evaluating Cisplatin or carboplatin-based concomitant chemoradiation versus radiotherapy alone in locally advanced non-small cell lung cancer. Presented at the 10th World Conference on Lung Cancer August 10-14, 2003, Vancouver, British Columbia, Canada.
• A Sandler, C Langer, P Bunn, L Einhorn A Randomized Phase III Trial Comparing CPT-11 (Irinotecan HCl; Camptosar Injection)/Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated, Extensive, Small-Cell Lung Cancer: A Hoosier Oncology Group Study LUN00-12. Poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL
• Karen Kelly, Nasser Hanna, Arthur Rosenberg, Paul Bunn, Jr., and Michael N. Needle. A Multi-Centered Phase I/II Study of Cetuximab in Combination with Paclitaxel and Carboplatin in Untreated Patients with Stage IV Non-Small Cell Lung Cancer: A Hoosier Oncology Group Study LUN01-25. Poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL
• Nasser Hanna, Frances A Shepherd, Rafael Rosell, Jose R Pereira, Filippo De Marinis, Frank V Fossella, Louis Kayitalire, Sofia Paul, Lawrence Einhorn, Paul A Bunn. A Phase III Study of Pemetrexed vs Docetaxel in Patients with Recurrent Non-Small Cell Lung Cancer (NSCLC) who were Previously Treated with Chemotherapy): A Hoosier Oncology Group Study LUN01-15. Presented at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL
• Nasser H. Hanna, Alan B. Sandler, Patrick J. Loehrer, Sr., Rafat Ansari, Sin-Ho Jung, Kathleen Lane and Lawrence H. Einhorn Maintenance Daily Oral Etoposide Versus No Further Therapy Following Induction Chemotherapy With Etoposide Plus Ifosfamide Plus Cisplatin In Extensive Small Cell Lung Cancer: A Hoosier Oncology Group Study LUN93-2. Accepted as a poster presentation with discussion for ASCO annual meeting May 12-15, 2001, San Francisco, CA. Proc Am Soc Clin Oncol 20: 2001 (abstr 1261)
• Bhatia S, Ng E, Ansari A, Bufill J, Litrell D, Monaco F, Hanna M, Einhorn LH, Sandler A. A Phase II Study of Paclitaxel and Gemcitabine in Patients with Advanced Non Small Cell Lung Cancer -A Hoosier Oncology Group (HOG) Trial LUN98-1. Accepted to the ASCO annual meeting May 20-23, 2000, New Orleans, Louisiana.
• Bhatia S, Sandler A, Ansari R, Monaco F, Einhorn LH. Phase II Study of Paclitaxel Carboplatin and Radiation Therapy for Locally Advanced or Inoperable Non-Small Cell Lung Cancer (NSCLC): A Hoosier Oncology Group and Walther Cancer Institute Trial LUN97-1. Accepted to the ASCO annual meeting May 15-18, 1999, Atlanta, GA
• Sandler A, Ansari R, Saxman S, Walker P, Wasielewski MJ, Monaco F, Hayes J, Einhorn LH. Phase III Trial of Maintenance Daily Oral VP-16 Versus No Further Therapy Following Induction Chemotherapy With VP-16 (V) Plus Ifosfamide (I) Plus Cisplatin (P) (VIP) In Extensive Small Cell Lung Cancer (SCLC): A Hoosier Oncology Group (HOG) Trial LUN93-2. Accepted to the ASCO annual meeting May 15-18, 1999, Atlanta, GA
• Mantravadi R, Sandler A, Montebello J, Ansari R, Nattam S, McClean J, Walker P, Einhorn L. A Phase III Hoosier Oncology Group Study of Thoracic Radiotherapy (TRT) Plus Cisplatin (P) and Vinblastin (V) With or Without Hydroxyurea (HX) for Locally Unresectable Non-Small Cell Lung Cancer (NSCLC). Hoosier Oncology Group and Walther Cancer Institute Trial LUN91-1. Accepted at the ASTRO annual meeting October 25-28 1998, Phoenix, AZ
• Sandler A, Nemunaitis J, Dehnam C, Cormier Y, von Pawel J, Niyikiza C, Nguyen B, Einhorn L. Phase III Study of Cisplatin (C) With or Without Gemcitabine (G) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). A Hoosier Oncology Group Trial LUN95-1. Accepted to the ESMO annual meeting November 23, 1998, Athens, Greece.
• Sonpavde G, Ansari R, Einhorn L. A Phase II Trial of Bolus Doxorubicin and 3-Hour Paclitaxel as Second-Line Chemotherapy of Small-Cell Lung Cancer: A Hoosier Oncology Group Trial. A Hoosier Oncology Group Trial LUN96-1. Accepted to the ASCO annual meeting May 16-19, 1998, Los Angeles, CA.
• Ng E, Sandler A, Einhorn L. A Phase II Study of Carboplatin Plus Gemcitabine in Non-Small Cell Lung Cancer (NSCLC). A Hoosier Oncology Group Trial LUN96-2. Accepted to the ASCO annual meeting May 16-19, 1998, Los Angeles, CA.
• Mantravadi R, Sandler A, Montebello J, Ansari R, McClean J, Nattam S, Walker P, Einhorn L. Randomized Phase III Study of Cisplatin (P) and Vinblastine (V) Followed by Thoracic Radiotherapy With or Without Hydroxyurea (HX) In Previously Untreated Limited Unresectable Non-Small Cell Lung Cancer (NSCLC). A Hoosier Oncology Group and Walther Cancer Institute Trial LUN91-1. Accepted to the ASCO annual meeting May 16-19, 1998, Los Angeles, CA.
• Sandler AB, Ansari R, Fisher W, Gonin R, Levy R, Einhorn LH. A Phase II Hoosier Oncology Group Study of VP-16 Plus Ifosfamide Plus Cisplatin (VIP) Plus Concurrent Radiation Therapy (XRT) for Previously Untreated Limited Small Cell Lung Cancer (SCLC). A Hoosier Oncology Group and Walther Cancer Institute Trial LUN87-1. Accepted to the World Conference on Lung Cancer August, 1997 Dublin, Ireland.
• Sandler AB, Ansari R, Fisher W, Gonin R, Levy R, Einhorn LH. A Phase II Hoosier Oncology Group Study of VP-16 Plus Ifosfamide Plus Cisplatin (VIP) Plus Concurrent Radiation Therapy (XRT) for Previously Untreated Limited Small Cell Lung Cancer (SCLC). A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial LUN93-2. Accepted to the ASCO Annual Meeting May 18-21, 1996, Philadelphia, PA.
• Sandler AB, Ansari R, McClean J, Fisher W, Dorr A, Einhorn LH. A Hoosier Oncology Group Phase II Study of Gemcitabine Plus Cisplatin in Non-Small Cell Lung Cancer (NSCLC): A Hoosier Oncology Group and Walther Cancer Institute Trial LUN93-4. Submitted to the ASCO Annual Meeting May 20-23rd, 1995, Los Angeles, California.
• Sandler A, Loehrer PJ, Ansari R, Gonin R, Wasielewski MJ, Einhorn LH. A Phase III Study of VP16 plus Cisplatin (VP) alone or with Ifosfamide (VIP) in Previously Untreated Patients (PTS) with Extensive Small Cell Carcinoma of the LUNG (SCLC) : A Hoosier Oncology Group and Walther Cancer Institute Trial LUN93-2. Accepted to the Seventh World Conference on Lung Cancer, June 26th – July 1st, 1994, Colorado Springs, Colorado.
• Ansari R, Loehrer PJ, Gonin R, Wasielewski MJ, Einhorn LH. A Phase III Study of VP16 plus Cisplatin (VP) alone or with Ifosfamide (VIP) in Previously Untreated Patients with Extensive Small Cell Carcinoma of the Lung (SCLC): A Hoosier Oncology Group and Walther Cancer Institute Trial LUN93-2. Slide presentation accepted to the ASCO Meeting, May 14-17th, 1994, Dallas, Texas.
• Sandler AB, Loehrer PJ, Ansari R, Logie KW, Mortimer J, Sridhar R, Einhorn LH. A Phase II Study of Daily Oral VP-16 Plus Ifosfamide Plus Cisplatin (poVIP) for Previously Treated Recurrent Small Cell Lung Cancer (SCLC): A Hoosier Oncology Group and Walther Cancer Institute Trial LUN87-1. Poster Presentation accepted to the ASCO Annual Meeting, May 14-17, 1994, Dallas, Texas.
• Blanke C, Ansari R, Tokars R, Fisher W, Pennington K, Mantravadi R, O’Connor T, Rynard S, Miller M, Einhorn L. A Phase III Trial of Thoracic Irradiation With or Without Cisplatin For Locally Advanced Non-small Cell Lung Cancer (NSCLC): A Hoosier Oncology Group Protocol LUN86-1. Proc Int’l Conference on Adjuvant Therapy of Cancer, 1993.
• Sandler A, Nichols C, Rynard S, Ansari R, Blanke C, Einhorn L: A Phase II Hoosier Oncology Group Trial using CODE Chemotherapy in Patients with Unresectable Stage III or IV Non-Small Cell Lung Cancer (NSCLC) LUN91-2. Proc Am Soc Clin Oncol, 1993.
• Mandanas RA, Loehrer PJ, Ansari R, Wheeler B, Einhorn LH: Carboplatin (CBDCA) Plus Alpha Interferon (IFNa-2a) in Metastatic Non-Small Cell Lung Cancer (NSCLC): A Hoosier Oncology Group (HOG) Phase II Trial LUN90-1. Proc Am Soc Clin Oncol, 1992.
• Faylona E, Loehrer P, Einhorn L, Ansari R, McClean J, Williams S: A Phase II Study of Daily Oral VP-16 + Ifosfamide + Cisplatin for Previously Treated Small Cell Lung Cancer (SCLC): A Hoosier Oncology Group Study (HOG) Trial LUN87-1. Proc Am Soc Clin Oncol, 1992.
• Ansari R, Tokars R, Fisher W, Pennington K, Mantravadi R, O’Connor T, Rynard S, Miller M, Einhorn L: A Phase III Study of Thoracic Irradiation With or Without Concomitant Cisplatin in Locoregional Unresectable Non-Small Cell Lung Cancer (NSCLC): A Hoosier Oncology Group Protocol LUN86-1. Slide presentation at the ASCO annual meeting May, 1991 in Houston, TX. Proc Am Soc Clin Oncol 10: 1991.
• Tokars R, Ansari R, Mantravadi R, Einhorn L, Fisher W, Pennington K, O’Connor T, Rynard S, Miller M: A Phase III Study of Thoracic Radiation With or Without Concurrent Cisplatin Chemotherapy in Locoregional Unresectable Non-Small Cell Carcinoma of the Lung: A Hoosier Oncology Group Protocol LUN86-1. Slide presentation at ASTRO meeting October, 1991 in Washington DC. Proc ASTRO: 1991.
• Saxman S, Logie K, Stephens D, Workman F, Scullin D, Loehrer PJ: Phase II Trial of Daily Oral Etoposide in Patients with Surgically Unresectable Non Small Cell Lung Cancer LUN88-6. Proc Am Soc Clin Oncol 9:142, l990.
• Miller JC, Loehrer PJ, Songer J, Pennington K, Ansari R, Turner S, Einhorn LH: VP l6, Ifosfamide and Cisplatin (VIP) in Extensive Small Cell Lung Cancer: A Hoosier Oncology Group Study LUN87-1. Proc Am Soc Clin Oncol 9:248, l990.
• Higgs D, Jaussaud J, Miller M: Quality of Life as an Outcome Variable in Clients Receiving Chemotherapy for Lung Cancer. Proc ONS (l989).
• Ansari R, Fisher W, Butler F, Pennington K, Drasga R, Sciortino D, Miller M, Einhorn L: Aggressive Chemotherapy of Extensive Non Small Cell Lung Cancer: A Trial of the Hoosier Oncology Group. Proc Am Soc Clin Oncol 8:242, l989.